Trial Profile
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer Patients With Intermediate/High Risk Primary Disease or Biochemical Recurrence After Treatment
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Gallium-68-P16-093 (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- Sponsors Five Eleven Pharma
- 16 Jul 2021 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.
- 16 Jul 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Dec 2021.
- 16 Jul 2021 Status changed from recruiting to active, no longer recruiting.